Review of clinical studies of CA 27.29 in breast cancer management

International Journal of Biological Markers

Volumn 14, Issue 1, 1999, Pages 36-39

  Beveridge, R A ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Breast cancer; CA 15 3; CA 27.29; Mucin markers

Indexed keywords

CA 15-3 ANTIGEN; CA 27.29 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; METASTASIS;

EID: 0032934906     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400107     Document Type: Conference Paper

References (11)

1. Hull SR, Bright A, Carraway KL, Abe M, Hayes DF, Kufe DW. Oligosaccharide differences in the DF-3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun 1989; 1: 261-7.
2. Bon G, Kenemans P, van Kamp G, Yedema C, Hilgers J. Review on the clinical value of polymorphic epithelial mucin tumor markers for the management of carcinoma patients. J Nucl Med Allied Sci 1990; 34 (Suppl 3): 151-62.
3. Hayes DF, Sekine H, Ohno T, Abe M, Keefe K, Kufe DW. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75: 1671-8.
4. Price MR, Rye PD, Petrakou E, et al. Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biology 1998; 19 (S1): 1-20.
5. Mayo JM, Arena FP. Performance of serum tumor markers in detection of metastatic breast cancer: Does lack of positive markers indicate poor prognosis? Proc Am Soc Clin Oncol 1997; 16: 638 (abstract).
6. Aspeslet L, Ballok J, Mansbach L, Maimonis PJ. A technical and clinical evaluation of 3 commercial MUC-1 breast cancer marker assays. Tumor Biology 1998; 19 (S2): 13 (abstract).
7. Leon A, Mione R, Gion M. ACS:180 BR Assay: Evaluation in primary breast cancer in comparison with CA 15.3. Tumor Biology 1998; 19 (S2): 65 (abstract).
8. Houser S, Maimonis P. An analytical and clinical comparison of ACS:180" BR' with two other breast tumor marker assays. Clin Chem 1997; 43: 1477 (abstract).
9. Chan DW, Beveridge RA, Muss H, et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997; 15: 2322-8.
10. Hayes DF, Zurawski VRJ, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 4: 1542-50.
11. Abbate I, Correale M, Musci MD, et al. Comparison of CA 27.29 with CA 15-3 in breast cancer. J Tumor Marker Oncol 1998; 8 (1): 69-72.